Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study is looking at a new treatment for people with multiple myeloma who have not responded well to other treatments. It involves taking three drugs together: ibrutinib, lenalidomide, and dexamethasone. Men and women are invited to participate.
This study is looking at a new treatment for people with multiple myeloma who have not responded well to other treatments. It involves taking three drugs together: ibrutinib, lenalidomide, and dexamethasone. Men and women are invited to participate.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.
This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: